developing therapeutics for alzheimer s disease progress and challenges

Download Book Developing Therapeutics For Alzheimer S Disease Progress And Challenges in PDF format. You can Read Online Developing Therapeutics For Alzheimer S Disease Progress And Challenges here in PDF, EPUB, Mobi or Docx formats.

Developing Therapeutics For Alzheimer S Disease

Author : Michael S. Wolfe
ISBN : 9780128021644
Genre : Medical
File Size : 58. 77 MB
Format : PDF, ePub
Download : 442
Read : 781

Get This Book


Developing Therapeutics for Alzheimer's Disease: Progress and Challenges provides a thorough overview of the latest advances toward the development of therapeutics for Alzheimer’s disease, along with the major hurdles that still must be overcome and potential solutions to these problems. Despite the lack of progress toward developing therapeutics that can slow or stop the progression of this disease, important discoveries have been made and many promising approaches are advancing in preclinical studies and clinical trials. This book outlines the special challenges related to specific targets and approaches, while presenting a realistic, comprehensive and balanced view of drug discovery and development in this area. Written by international leaders in the field, the book assesses prospects for the emergence of effective agents and allows readers to better understand the challenges, failures, and future potential for research in Alzheimer’s disease. This book is a valuable resource to academic scientists carrying out translational research in Alzheimer’s disease, industrial scientists engaged in Alzheimer's drug discovery, executives in biopharmaceutical companies making strategic decisions regarding the direction of internal research and potential outside partnerships, and graduate-level students pursuing courses on Alzheimer's therapeutics. Provides a realistic but promising assessment of the potential of various therapeutic approaches to Alzheimer’s disease Focuses primarily on neuroprotective agents and cognitive enhancers, as well as approaches to targeting the amyloid B-peptide, tau and Apolipoprotein E Discusses alternative approaches, preclinical and clinical development issues, related biomarkers and diagnostics, and prevention and nonpharmacological approaches

Comprehensive Medicinal Chemistry Iii

Author :
ISBN : 9780128032015
Genre : Science
File Size : 44. 83 MB
Format : PDF, ePub, Mobi
Download : 450
Read : 597

Get This Book


Comprehensive Medicinal Chemistry III provides a contemporary and forward-looking critical analysis and summary of recent developments, emerging trends, and recently identified new areas where medicinal chemistry is having an impact. The discipline of medicinal chemistry continues to evolve as it adapts to new opportunities and strives to solve new challenges. These include drug targeting, biomolecular therapeutics, development of chemical biology tools, data collection and analysis, in silico models as predictors for biological properties, identification and validation of new targets, approaches to quantify target engagement, new methods for synthesis of drug candidates such as green chemistry, development of novel scaffolds for drug discovery, and the role of regulatory agencies in drug discovery. Reviews the strategies, technologies, principles, and applications of modern medicinal chemistry Provides a global and current perspective of today's drug discovery process and discusses the major therapeutic classes and targets Includes a unique collection of case studies and personal assays reviewing the discovery and development of key drugs

Preclinical And Clinical Issues In Alzheimer S Disease Drug Research And Development

Author : Cesare Mancuso
ISBN : 9782889194339
Genre :
File Size : 54. 73 MB
Format : PDF, ePub, Docs
Download : 345
Read : 217

Get This Book


Alzheimer’s disease (AD) is a chronic neurodegenerative disorder characterized by progressive cognitive dysfunction and memory loss, inability to perform the activities of daily living and mood disorders. According to the so-called “amyloid cascade hypothesis”, amyloid-ß- peptide (Aß), produced by beta- and gamma- secretase-mediated cleavages of the amyloid precursor protein (APP), plays a pivotal role in the pathogenesis of AD. Aß was also shown to contribute to AD pathology by stimulating the hyperphosphorylation of tau which is responsible for the formation of neurofibrillary tangles. However, the “amyloid cascade hypothesis” was challenged by other theories which lend support to the idea that Aß is not causative but can be considered as an “innocent bystander” in AD. Although preclinical research generated impressive lines of evidence about the several intracellular mechanism(s) whose impairment leads to the onset and progression of AD, clinical research aimed at the development of new drugs capable of preventing or delaying the onset of neuronal damage in AD patients has produced limited results. The drugs currently available for the treatment of AD are acetylcholinesterase inhibitors (AChEI) and the NMDA glutamate receptor antagonist memantine. The AChEI increase acetylcholine levels in the synaptic cleft, which are reduced because of the progressive damage of cholinergic neurons in cognitive brain areas (e.g. amygdala, hippocampus, and frontal cortex), whereas memantine is used to prevent/reduce calcium-dependent excitotoxic neuronal cell death. Both classes of drugs have been shown to improve symptoms related to cognitive decline, but their effects are confined largely to patients with mild to moderate AD, in particular during the first year or so of treatment. An alternative to this symptomatic treatments involves the use of drugs that intervene in the pathogenesis of the disease. Recently, monoclonal antibodies against Aß were proposed as novel agents capable to remove Aß from the brain thus preventing neuronal damage. The research topic focuses on the preclinical and clinical evidence about the several factors that contribute to the pathogenesis of AD as well as the potential therapeutic role of new classes of drugs still under preclinical or clinical development.

Animal And Translational Models For Cns Drug Discovery Neurological Disorders

Author : Robert A. McArthur
ISBN : 0080920381
Genre : Medical
File Size : 36. 44 MB
Format : PDF, ePub, Docs
Download : 403
Read : 704

Get This Book


Neurological Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for neurological disorders such as neurofibromatosis, Alzheimer’s disease, Parkinson’s disease, Huntington disease, ALS, and the epilepsies. Neurological Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the second volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually. Clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process Critical evaluation of animal and translational models improving transition from drug discovery and clinical development Emphasis on what results mean to the overall drug discovery process Exploration of issues in clinical trial design and conductance in each therapeutic area

Animal And Translational Models For Cns Drug Discovery

Author : Robert A. McArthur
ISBN : 0080920411
Genre : Medical
File Size : 46. 60 MB
Format : PDF, Kindle
Download : 402
Read : 280

Get This Book


Animal and Translational Models for CNS Drug Discovery combines the experience of academic, clinical and pharmaceutical neuroscientists in a unique collaborative approach to provide a greater understanding of the relevance of animal models of neuropsychiatric disorders and their role as translational tools for the discovery of CNS drugs being developed for the treatment of these disorders. The focus of this three-volume series of essays is to present a consensual picture of the translational value of animal models from leading experts actively involved in the use of animal models for understanding fundamental neurobiology of CNS disorders and the application of this knowledge to CNS drug discovery, and clinical investigators involved in clinical trials, drug development and eventual registration of novel pharmaceuticals. Each volume of the Animal and Translational Models for CNS Drug Discovery series is dedicated to the development and use of animal models in key therapeutic areas in psychiatric, neurologic and reward deficit disorders. Each volume has introductory chapters expressing the view of the role and relevance of animal models for CNS drug discovery and development from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in relevant therapeutic areas and discusses the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. - Provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process - Critical evaluation of animal and translational models improving transition from drug discovery and clinical development - Emphasizes what results mean to the overall drug discovery process - Explores issues in clinical trial design and conductance in each therapeutic area - Each volume is available for purchase individually.

The Neuropsychology Of Cortical Dementias

Author : Mary Anderson, PhD
ISBN : 9780826107275
Genre : Psychology
File Size : 62. 29 MB
Format : PDF
Download : 352
Read : 714

Get This Book


"This book provides an overview of the cognitive and behavioral profiles of the cortical dementias in a readable and clinically relevant manner. Its emphasis on disease entities primarily affecting cortical structures allows for a more comprehensive description of the latest insights into the pathogenesis and assessment of a number of different disease processes... Weighted Numerical Score: 98 - 5 Stars!" Melissa Jones, MD (University of Illinois at Chicago College of Medicine) Doody's Medical Reviews The Neuropsychology of Cortical Dementias addresses in depth the neuropsychological impact and features of the full range of cortical dementias. It examines the differential neuropathological and pathophysiological bases of these dementias and emphasizes their behavioral and cognitive aspects in assessment, diagnosis, and treatment. The book also presents the most advanced techniques and strategies for disease-specific treatment. Important legal/ethical issues and the role of caregivers in treating dementia patients are also covered. Featuring contributions from such diverse disciplines as neuropsychology, neurology, psychiatry, and clinical psychology, this volume provides a broad interdisciplinary perspective for practicing clinical neuropsychologists, neurologists, psychiatrists, gerontologists, and psychologists who work with patients with dementia. Key Features: Includes comprehensive, clinically focused coverage of all major cortical dementias Covers neuroanatomy, assessment, diagnosis, treatment, and management of dementia patients, as well as legal and ethical issues Discusses assessment and diagnosis from the perspectives of neuroimaging and cognitive and behavioral symptoms Discusses a range of interventions (pharmacological, cognitive behavioral, etc.) and management issues related to dementia treatment Informed by contributions from such diverse disciplines as neuropsychology, neurology, psychiatry, and clinical psychology

Biomarkers In Brain Disease

Author : Simon Lovestone
ISBN : STANFORD:36105133110309
Genre : Medical
File Size : 23. 2 MB
Format : PDF, ePub, Mobi
Download : 716
Read : 1311

Get This Book


Advances in biomarker development are revolutionizing the way we study, diagnose and treat disease. However, progress in the development and use of biomarkers for diseases of the central nervous system has been limited by a number of difficulties -- including the inherent barriers associated with studying the brain. Development of reliable biomarkers for brain disorders would dramatically accelerate research on the etiology, pathophysiology, disease progression, and therapeutic development of many very prevalent and devastating diseases including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and others. International experts in the field have contributed chapters to this volume that discuss the latest advances in biomarker technologies and biomarker development for brain disorders, as well as the logistical, regulatory and funding challenges experienced by scientists working on clinical trials for biomarkers NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas. ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.

Alzheimer S Disease

Author : Inga Zerr
ISBN : 9789535121374
Genre : Medical
File Size : 85. 30 MB
Format : PDF, Mobi
Download : 249
Read : 217

Get This Book


There is a wide scope of clinical phenomenology in Alzheimers disease, regarding the age of onset, presenting features, rate of progression and appearance of other clinical manifestation. Although clinical appearance and neuropathological hallmarks have been defining AD since its first description, major factors which trigger pathology are still unknown. The role of comorbidity is discussed controversially. Important environmental risk factors in AD development are continuous stress, low education and cardiovascular risk factors such as alcohol intake, smoking, hypertension. The role of lipids and cholesterol has been recognized, but the relevant pathogenetic steps are still to be identified. There is an urgent need to understand molecular disease pathogenesis in order to develop early therapeutic targets for the disease.

Imaging In Neurodegenerative Disorders

Author : Luca Saba
ISBN : 9780191651403
Genre : Medical
File Size : 71. 22 MB
Format : PDF, Docs
Download : 844
Read : 1012

Get This Book


Diagnosing neurodegenerative diseases can prove particularly intimidating to clinicians, because many times the diagnosis cannot be critically "confirmed" by a simple test. New imaging modalities have advanced to the point of high resolution, morphological, metabolic and functional analysis. Computed tomography, magnetic resonance, nuclear medicine and molecular imaging have recently emerged as outstanding non-invasive techniques for the study of the neurodegenerative disorders. Imaging in Neurodegenerative Disorders covers all the imaging techniques and new exciting methods like new tracers, biomarker, metabolomic and gene-array profiling, potential for applying such techniques clinically, and offers present and future applications as applied to the neurodegenerative disorders with the most world renowned scientists in these fields. This book is an invaluable resource for researchers, clinicians, and trainees in neuroscience, neurology, psychiatry, and radiology.

Research Progress In Alzheimer S Disease And Dementia

Author : Miao-Kun Sun
ISBN : 1600212719
Genre : Medical
File Size : 24. 58 MB
Format : PDF
Download : 862
Read : 927

Get This Book


Alzheimer's disease (AD), the most common type of neurodegenerative disorder in the aging population, is characterised pathologically by extracellular amyloid plaques and intracellular neurofibrillary tangles, pathophysiologically by synaptic dysfunction, and clinically by a progressive dementia. The rapid progress in the research fields of AD and dementia continues since the publication of the first book volume with the same title. This second book volume contains 14 chapters, bringing together a presentation of research frontiers in current AD/dementia research. The topics range from defining deregulation of amyloid precursor protein (APP) processing and neurotransmitter and signal molecules involved in regulation of APP processing, transgenic AD mouse models and their relevance to AD research, amyloid -peptide (A) immunisation, cerebral inflammation, myelin breakdown, roles of deregulation of cell cycle in AD pathology, relationship between cholesterol and AD, A binding to cholesterol and cholesterol oxidation, A-binding alcohol dehydrogenase and roles in AD pathogenesis, sex steroids, oestrogen therapy for AD prevention, behavioural and psychological symptoms of AD, memantine for AD therapy, enoxaparin as a therapeutic agent for AD, to molecular links between AD and traumatic brain injury. The prospects for developing effective therapeutic agents that target memory-relevant AD pathogenesis, as shown in these chapters written by world-wide leaders in the fields, are more encouraging. The book will be highly valuable to students and scientists world-wide who are interested in the scientific research progress in AD and dementia.

Top Download:

Best Books